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Abstract To investigate interactions between the polyehlori- 
nated biphenyl-binding protein uteroglobin and phospholipids, we 
used a liposome-pelletting assay. PCB-BPluteroglobin bound to 
liposomes made from negatively charged phospholipids (PtdSer 
and Ptdlns) in the presence of 5 mM calcium. No binding to 
liposomes made from phospholipids without net charge (PtdChol 
and PtdEtn) was observed, nor could we detect binding in the 
absence of calcium or when magnesium was substituted for cal- 
cium. This suggests that PCB-BPluteroglobin can bind to 
phospholipids in vivo and may have a role in the phospbolipid 
homeostasis of the airway and/or secretory pathway of the Clara 
cell. 
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1. Introduction 
Rabbit uteroglobin [1] and the homologous rat and human 
proteins are low molecular mass homodimeric proteins that 
bind metabolites ofpolychlorinated biphenyls (PCBs) with high 
affinity [2-4]. Thus, they are also known as PCB-binding pro- 
teins (PCB-BPs). Moreover, commonly used names are Clara 
cell secretory protein (CCSP) and Clara cell 10-kDa protein 
(CC10) since they are secreted in large amounts from the non- 
ciliated Clara cell in the distal airway epithelium [5-8]. PCB-BP/ 
uteroglobin s a major constituent of the lining fluid in the distal 
conducting airways [9]. In uterus, high level expression is seen 
in the endometrial cells during the luteal phase of the human 
menstrual cycle [10]. Furthermore, PCB-BP/uteroglobin is ex- 
pressed uring early pregnancy in rabbit [1]. The protein has 
also been identified in male reproductive organs in rabbit and 
human [11,12]. 
The structure of PCB-BP/uteroglobin has been extensively 
studied and three-dimensional structures based on X-ray dif- 
fraction data exist for the rabbit, rat and human protein [13- 
15]. Although several hypotheses xist regarding the physiolog- 
ical role of PCB-BP/uteroglobin (recently reviewed by Miele et 
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al., 1994 [16]), a clear in vivo role has yet to be determined. In
addition to binding metabolites of polychlorinated biphenyls 
[2~], it also binds progesterone, although with lower affinity 
[17 19]. Furthermore, we have recently shown that human 
PCB-BP/uteroglobin binds calcium [20]. The putative calcium- 
binding site of PCB-BP/uteroglobin shows similarities to the 
calcium-binding site of secretory phospholipase A2s (sPLA2s; 
Barnes et al., manuscript in prep.) and is, thus, also similar to 
calcium-binding sites in proteins from the annexin family [21]. 
In sPLA2s, calcium binding is necessary for enzyme activity and 
in annexins it mediates calcium-dependent phospholipid inter- 
actions (for recent reviews, see, e.g. Dennis et al., 1994 [22], and 
Raynal et al., 1994 [23]). Interestingly, phospholipids were re- 
cently found inside the hydrophobic avity of PCB-BP/uter- 
oglobin isolated from human sources [15]. In light of these 
findings, we wanted to investigate whether human PCB-BP/ 
uteroglobin can interact with phospholipid bilayers. To this 
end, we used a liposome-pelleting assay previously used to 
characterize annexin-phospholipid interactions. 
2. Materials and methods 
2.1. Chemicals 
All chemicals were purchased from Merck (Germany) unless other- 
wise stated. 
2.2. Plasmids and bacterial expression 
Expression of recombinant human PCB-BP/uteroglobin was carried 
out as previously described [20]. Briefly, the coding sequence for human 
PCB-BP/uteroglobin (kindly provided by Dr. G. Suske, Institut fiir 
Molekularbiologie und Tumorforschung, Marburg, Germany) w s 
subcloned inan expression plasmid containing both lac and T7 promot- 
ers. Included was also a T-extension encoding four histidines. Recom- 
binant protein was expressed in the E. coli strain BL21(DE3) and the 
Hisa-tagged protein was purified via chromatography on a NiZ÷-Sepha - 
rose (Pharmacia Biotech, Sweden) column followed by FPLC. Trace 
metal ions were removed by treatment with 0.5g chelex (BioRad, CA) 
per 100 rng protein. The His 4 tag did not change the phospholipid- 
binding characteristics as judged by comparison to non-tagged recom- 
binant human PCB-BP/uteroglobin (data not shown). 
2.3. Liposome preparation and pelletting assay 
Liposomes were prepared according to Jost et al. (1994) [24]: 
phospholipids (purchased in chloroform or chloroform : methanol solu- 
tion from Sigma, MO) were dried down under N2 and resuspended in 
40/IM EGTA. After sonication, liposomes were pelleted at 200,000 x g
for 20 min, resuspended in 40/IM EGTA at a concentration f 7.5 
mg/ml and stored under N v The pelleting assay, modified from Jost et 
al. (1994) [24], was carried out as follows: 50 mg protein was preincu- 
bated in 90 H1 of 50 mM imidazole-HC1 (pH 7.5), 150 mM NaCI and 
either 5 mM CaCI:, 5 mM MgCI2 or 10 mM EDTA for 20 min at 20°C 
with shaking. Liposomes w re added to a final concentration of 
3 mg/ml and incubated with shaking for an additional 20 min. Li- 
posomes and bound protein were then pelleted at 200,000 x g for 20 min 
at room temperature. Bound protein was subsequently eluted from the 
pellet with a buffer containing imidazole and NaC1 as above and 100 
mM EDTA (20 min with shaking at20°C). Remaining liposomes were
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pelletted as before and the supernatants were loaded onto SDS-PAGE 
gels (without reducing agent). The gels were analysed through Coomas- 
sie brilliant blue G250 staining (Serva, Germany) [25]. 
2.4. Phospholipid-binding assay 
Phosphatidyl inositol liposomes with tritiated phosphatidyl inositol 
(Amersham Life Sciences, UK) included to a specific activity of 2.5 
Ci/mol were prepared as escribed in section 2.3. Recombinant protein 
was then incubated with increasing concentrations of phopspholipid in 
50 mM imidazole-HC1 (pH 7.5), 150 mM NaCI, 5 mM CaCI2, I mM 
DTT and 1 mg/ml ovalbumin (Sigma). To correct for unspecific bind- 
ing, incubations without recombinant protein were carried out in paral- 
lel. After overnight incubation t 37°C with shaking, samples were 
transferred to ice. EDTA wasadded to a concentration of 10 mM to 
brake liposom~protein interactions and liposomes were pelletted at 
200,000 x g at 4°C. Radioactivity in the supernatant was then deter- 
mined by scintillation counting. Non-pellettable, i. . non-liposomal, 
PtdIns then represents total protein-bound phospholipid as well as free 
phospholipids in solution. Thus, differences in radioactivity between 
incubations with and without recombinant human PCB-BP/uter- 
oglobin will represent specific binding of PtdIns to the protein. PtdIns 
concentration in the supernatant was plotted as a function of PtdIns 
concentration in the incubation before pelletting and linear regression 
analysis was used to fit straight lines for incubations with and without 
recombinant PCB-BP/uteroglobin. Other incubation temperatures 
tested (4, 20 and 30°C) did not affect he result (data not shown). 
Finally, incubations (without ovalbumin added) were analysed by 5 
20% (w/v) linear sucrose gradients as de cribed previously [18]. Stand- 
ard proteins (aldolase, ovalbumin and cytochrome c; all from Sigma) 
as well as recombinant PCB-BP/uteroglobin were run in parallel to 
determine the expected position of radiolabelled PtdIns bound to PCB- 
BP/uteroglobin. 
3. Results 
3.1. Binding of PCB-BP/uteroglobin to phospholipid liposomes 
To test whether human PCB-BP/uteroglobin can bind to 
phospholipid liposomes, we incubated recombinant human 
PCB-BP/uteroglobin with liposomes prepared from either 
phosphatidyl choline (PtdChol), phosphatidyl serine (PtdSer), 
phosphatidyl ethanolamine (PtdEtn) or phosphatidyl inositol 
(Ptdlns). Subsequently, liposomes were pelletted and bound 
protein was eluted and analysed by SDS-PAGE and Coomassie 
blue staining. The incubations were done in the presence of 
either 5 mM Ca 2+ or 10 mM EDTA. As seen in Fig. 1, PCB-BP/ 
uteroglobin binds to negatively charged phospholipid li- 
posomes (PtdSer and Ptdlns) but not o phospholipids without 
net charge (PtdChol and PtdEtn). The binding is calcium-de- 
pendent and very little binding occurs in the presence of EDTA 
(Fig. 1 ). Calcium-dependent binding of PCB-BP/uteroglobin to 
liposomes made from a mixture ofPtdChol, PtdEtn, Ptdlns and 
lyso-PtdChol (4:3:2:1) was also observed (data not shown). 
No binding of PCB-BP to liposomes was detected when only 
~M concentrations of calcium were included (data not 
shown). 
We next wanted to test he cation dependency of liposome 
binding. Therefore, PCB-BP/uteroglobin was incubated with 
phosphatidyl serine liposomes in either 5 mM Ca 2+, 5 mM Mg 2÷ 
or 10 mM EDTA and analysed as before. Magnesium was used 
since, with the exception of calcium, it is the only divalent metal 
ion present in mM concentration in vivo. PCB-BP/uteroglobin 
did not bind to phosphatidyl serine liposomes in the presence 
of magnesium ions (Fig. 2, lane 3). As before, PCB-BP/uter- 
oglobin bound to phosphatidyl serine liposomes in the presence 
of calcium but not in the presence of EDTA (Fig. 2, lanes 4 and 
2). 
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Fig. 1. Calcium-dependent binding of PCB-BP/uteroglobin to nega- 
tively charged phospholipid liposomes but not to phospholipids with- 
out net charge. 2 and 10 pg recombinant human PCB-BP were included 
on the gels as positive controls (PH4). Positions of molecular weight 
markers indicated at left. 
3.2. Binding of phosphatidyl inositol to PCB-BP/uteroglobin 
The observed association of human PCB-BP/uteroglobin to 
phosphatidyl inositol iposomes prompted us to investigate if 
this might be related to the binding of single PtdIns molecules 
inside human PCB-BP/uteroglobin [15]. One possibility might 
be that the physical interaction of the protein with the liposome 
would allow it to extract phospholipids into its ligand-binding 
cavity. We, therefore, designed experiments where we incu- 
bated recombinant human PCB-BP/uteroglobin with liposomes 
made from radiolabelled PtdIns under conditions where PCB- 
BP/uteroglobin binds to PtdIns liposomes. After pelletting, the 
liposomes in the presence of EDTA, which disrupts PCB-BP/ 
uteroglobins interaction with the liposome, radioactivity in the 
supernatant will represent total protein-bound PtdIns as well 
as free non-liposomal Ptdlns. Comparisons between incuba- 
tions with and without recombinant human PCB-BP/uter- 
oglobin then provide an estimate of PCB-BP/uteroglobin-spe- 
cific binding. As shown in Fig. 3A, no additional retention of 
PtdIns in the supernatant can be seen in the presence of 10 pM 
recombinant human PCB-BP/uteroglobin (compare filled and 
empty circles), thus, suggesting that binding of PtdIns to PCB- 
BP/uteroglobin does not take place under these conditions. To 
verify this, the supernatant indicated in Fig. 3A was ubjected 
to a linear sucrose gradient. This revealed no increased radioac- 
tivity in the fractions where PCB-BP/uteroglobin is expected to
accumulate (Fig. 3B), further indicating that no binding of 
phosphatidyl inositol to human PCB-BP/uteroglobin occurs 
under the conditions applied here. 
4. Discussion 
In the present study, we show that human PCB-BP/uter- 
oglobin can bind to anionic phospholipid liposomes in a cal- 
cium-dependent manner. The presence of negatively charged 
phospholipids in the liposomes i required. The binding is seen 
only with calcium concentrations i  the mM range and magne- 
sium cannot substitute for calcium. 
The putative calcium-binding site of PCB-BP/uteroglobin 
shows similarities to calcium-binding sites of the phospholipid 
interacting secretory PLA2s (Barnes et al., manuscript in prep.) 
and annexins [21]. Annexins bind to negatively charged 
phospholipids in the presence of/IM calcium [23]. In contrast, 
PCB-BP/uteroglobin needs calcium concentrations i  the mM 
range. Calcium concentrations i  the lining fluid of conducting 
airways has been reported to be around 4 mM in humans [26]. 
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Thus, PCB-BP/uteroglobin teraction with anionic phosphol- 
ipids may very well be possible in the airway lining fluid of the 
small airways. Studies of the subcellular localization of PCB- 
BP/uteroglobin i  Clara cells show the protein to be present 
preferentially in endoplasmic reticulum and in secretory gran- 
ules [6]. Calcium concentrations within the endoplasmic reticu- 
lum are considered to be approximately 2 mM, whereas ecre- 
tory granules often contain higher concentrations (typically 
2040 mM; see Meldolesi et al., 1990 [27], and references 
therein). Thus, the potential for phospholipid interactions ex- 
ists in these organelles as well. Moreover, PCB-BP/uteroglobin 
has recently been shown to bind to microsomes and plasmatic 
membranes. A different mechanism seems involved in this case, 
as PCB-BP/uteroglobin was associated with binding compo- 
nent(s) with an apparent Mr of 90,000, suggesting the presence 
of a membrane-associated uteroglobin-binding protein [28]. 
Nevertheless, it is noteworthy that these experiments were car- 
ried out in buffers containing 5 mM calcium. 
Negatively charged phospholipids (PtdSer and PtdIns) seem 
to be more abundant in the lining fluid of the conducting 
airways than in the lining fluid of the alveoli, as judged from 
analysis of phospholipids in human bronchial lavage (BL) and 
bronchoalveolar lavage (BAL). PtdSer and PtdIns comprise 
approximately 25% of total phospholipids in BL and only 5% 
of total phospholipids in BAL [29]. Thus, PCB-BP/uteroglobin 
binding to phospholipids appears more likely in the conducting 
airways than in the alveolar lining, i.e. the pulmonary surfac- 
tant, where phosphatidyl choline predominates [30]. This is in 
agreement with data from our laboratory showing that PCB- 
BP/uteroglobin cannot be detected in surfactant preparations 
of rat lung (Nord et al., unpubl, data). 
One described property of PCB-BP/uteroglobin is its anti- 
inflammatory effects. These have primarily been correlated to 
PCB-BP/uteroglobin's ability to inhibit secretory PLA 2 in vitro 
[reviewed in 16]. Since PLA2s are considered to act optimally 
when the phospholipid substrate is part of a lipid-water inter- 
face, as for instance a membrane [22], the binding of PCB-BP/ 
uteroglobin to phospholipid bilayers might allow it to interact 
with PLA2s at their site of action. Besides direct PCB-BP/ 
uteroglobin-PLA2 interactions, the binding of PCB-BP/uter- 
oglobin to phospholipids and/or the binding of phospholipids 
inside the protein [15] offers a potential mechanism for PLA2 
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Fig. 2. Binding of PCB-BP/uteroglobin to negatively charged phospho~ 
lipid liposomes is dependent on calcium but not magnesium. 2/lg 
recombinant human PCB-BP was included on the gel as a positive 
control (PH4). Positions of molecular weight markers indicated at left. 
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Fig. 3. PCB-BP/uteroglobin does not bind phosphatidyl inositol. 
(A) Non-liposome-associated PtdIns as a function of PtdIns added to 
the incubation (presented as a lin-log graph for a clearer view of low 
PtdIns concentrations). Straight lines were fitted bylinear regression 
to points representing experiments with (filled circles) and without 
(empty circles) 10/IM recombinant human PCB-BP/uteroglobin. R 
values are indicated for each fit. Also indicated is the point analysed 
by sucrose gradients in B. (B) Quantification of radioactive PtdIns in 
5-20% linear sucrose gradients. Indicated are the positions of standard 
proteins and their respective S values, as well as the position of recom- 
binant PCB- BP/uteroglobin. 
inhibition by substrate blockage/sequestring. However, in stud- 
ies on the inhibition of secretory PLA2s by PCB-BP/uteroglobin 
from our group and others [20 and references therein], this does 
not seem to be the case, as increasing the amount of phospho- 
lipid substrate does not overcome the inhibition. Moreover, our 
study also shows that the in vitro inhibition is a consequence 
of the calcium-binding activity of PCB-BP/uteroglobin [20]. 
The protein sequesters calcium, an essential cofactor for 
sPLAzs and no inhibition occurs in the presence of mM 
amounts of calcium. Still the potential in vivo colocalization of 
PCB-BP/uteroglobin with PLA2s at phospholipid membranes 
might allow local effects on calcium concentrations. In conclu- 
sion, the anti-inflammatory/PLAz inhibitory properties of 
PCB-BP/uteroglobin are complex and not completely under- 
stood. Investigating the structure-function relationships of 
PCB-BP/uteroglobin, especially with regard to its calcium- and 
phospholipid-binding properties, eems especially important to 
further our understanding in these matters. 
Recently, phosphatidyl inositol and phosphatidyl choline 
was found inside the hydrophobic avity of PCB-BP/uter- 
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oglobin isolated from human sources [15]. Access to this hydro- 
phobic cavity probably requires reduction of the disulfide 
bridges in the protein. Reduction has been suggested to allow 
conformational changes that might mediate interactions with 
lipid membranes [15], providing a mechanism for conforma- 
tionally regulated uptake of phospolipids. The calcium-depend- 
ent binding of PCB-BP/uteroglobin to phospholipid bilayers 
might then provide further mechanisms for the protein to get 
in close proximity and interact with its potential ligand. Never- 
theless, we could not uncover any binding of Ptdlns to human 
PCB-BP/uteroglobin under the conditions allowing PCB-BP/ 
uteroglobin to bind to liposomes that we describe here. Since 
the Ptdlns concentration i epithelial lining fluid of human 
airways has been reported to be around 60/2M [31] and most 
of epithelial lining fluid phospholipids i  in the form of surfac- 
tant, the conditions tested here (Ptdlns presented in the form 
of liposomes in concentrations ranging from 5 to 300/zM) 
appear physiologically relevant. Other attempts by our labora- 
tory to study the binding of Ptdlns to human PCB-BP/uter- 
oglobin has included direct binding assays using other vehicles 
than liposomes to deliver the phospholipid, as well as competi- 
tion assays using Ptdlns in liposomes to compete with binding 
of radiolabelled progesterone. However, none of these assays 
have been successful in showing binding of Ptdlns to PCB-BP/ 
uteroglobin (data not shown). One possibility is that the bind- 
ing of phosphatidyl inositol in the ligand-binding cavity may 
require unknown additional factor(s) which are normally pres- 
ent in vivo. 
In conclusion, our study shows that PCB-BP/uteroglobin can 
bind to phospholipid liposomes under conditions present in the 
conducting airways and intracellularly in endoplasmic reticu- 
lum and secretory granules. Thus, it provides a mechanism 
whereby PCB-BP/uteroglobin can get in close proximity to 
phospholipid bilayers in vivo. Even though we have been una- 
ble to demonstrate binding of phosphatidyl inositol to PCB-BP/ 
uteroglobin in vitro, these data together with the finding of 
phospholipids inside the hydrophobic avity of PCB-BP/uter- 
oglobin [15] suggest a role for PCB-BP/uteroglobin  the phos- 
pholipid homeostasis of the airways and/or the secretory path- 
way of the Clara cell. 
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